iX Biopharma cuts loss in FY 2025

The group’s revenue grew by 30% year on year to $7.7m.

iX Biopharma has narrowed its loss to $10.1m for the financial year 2025, compared to a $10.8m loss during the same period last year.

The group’s revenue grew by 30% year on year to $7.7m. Despite weaker consumer spending in Australia, Speciality Pharmaceuticals grew its revenue by 22% driven by strong sales of medicinal cannabis products and services in Australia.

The Nutraceuticals segment also grew more than twofold, primarily from new engagements in the PRC, USA, Europe and the Middle East.

Despite higher revenue, the group’s cost of sales increased due to a different revenue mix and economies of scale.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia